Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

56.33
-0.6300-1.11%
Post-market: 57.180.8526+1.51%19:59 EDT
Volume:6.22M
Turnover:349.67M
Market Cap:7.89B
PE:38.19
High:58.00
Open:56.79
Low:54.89
Close:56.96
52wk High:76.76
52wk Low:9.57
Shares:140.01M
Float Shares:120.00M
Volume Ratio:2.48
T/O Rate:5.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.48
EPS(LYR):-0.0122
ROE:75.50%
ROA:14.35%
PB:13.87
PE(LYR):-4,619.86

Loading ...

Arrowhead Pharmaceuticals - Aro-Inhbe Monotherapy Achieves -9.9% Visceral Fat Reduction

THOMSON REUTERS
·
Jan 06

Arrowhead Pharmaceuticals Announces Interim Clinical Data on Rnai-Based Obesity Candidates Showing Weight Loss in Obese Patients With Diabetes and Improved Measures of Body Composition

THOMSON REUTERS
·
Jan 06

Arrowhead Pharmaceuticals CEO Christopher Richard Anzalone Reports Disposal of Common Shares

Reuters
·
Jan 06

Health Canada Approves Arrowhead's REDEMPLO for Familial Chylomicronemia Syndrome

Reuters
·
Jan 05

Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo™ (Plozasiran) to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
Jan 05

Arrowhead Pharmaceuticals : Bernstein Raises Target Price to $35 From $17

THOMSON REUTERS
·
Jan 02

U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Block, Terawulf

Reuters
·
Jan 02

Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Disposal of Common Shares

Reuters
·
Dec 31, 2025

Arrowhead Pharmaceuticals CFO William D. Waddill Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

Arrowhead Pharmaceuticals Director Victoria Vakiener Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

Arrowhead Pharmaceuticals Chief Medical Officer Adeoye Y. Olukotun Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

Arrowhead Pharmaceuticals Showcases Clinical Data at Major Industry Events

Reuters
·
Dec 23, 2025

U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla

Reuters
·
Dec 23, 2025

From on-device AI to the 'girlfriend index,' trading ideas from the research firm that nailed 2025's investment themes

Dow Jones
·
Dec 18, 2025

Arrowhead Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Dec 17, 2025

Arrowhead Pharmaceuticals : Piper Sandler Raises Target Price to $100 From $70

THOMSON REUTERS
·
Dec 17, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025

Arrowhead Pharmaceuticals CEO Christopher Richard Anzalone Reports Sale of Common Shares

Reuters
·
Dec 17, 2025

BRIEF-Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Dec 16, 2025

Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress

Simply Wall St.
·
Dec 15, 2025